HOME >> BIOLOGY >> NEWS
Geisinger scientist seeks cure for Lou Gehrig's disease, creating device to find treatment

DANVILLE- A small tropical fish, the curiosity of a Geisinger research scientist and some college students have created the perfect storm of sorts in an attempt to find a cure for one of the worlds most devastating neurological diseases.

On initial glance, there doesnt seem to be much in common between zebrafish, researcher Glenn S. Gerhard, MD and a trio of Bucknell University biomedical engineering students. Yet theyre each playing a critical role in clearing a major roadblock in the search for a cure for Lou Gehrig's disease.

Lou Gehrig's disease-or ALS or amyotrophic lateral sclerosis is a fatal neurodegenerative condition that affects nerve cells in the brain and the spinal cord. As many as 20,000 Americans suffer from ALS and about 5,000 people in the U.S. are diagnosed with the disease each year, according to the National Institutes of Health.

Its an aging-related disease that has long fascinated Gerhard, a staff scientist in Geisingers Weis Center for Research.

Gerhard believes that the cure for the diseaseor at least a more viable treatment optioncan be found in the right mix of the millions of drugs and drug compounds that have been developed in laboratories across the world.

There are so many different compounds but you dont know which ones to test, Gerhard says. We need bioengineering help to automate this process.

Thats why Gerhard turned to the zebrafish and Bucknell University professor Joe Tranquillo and students Erica Andreozzi, Meredith Kalman and Emily Thiel.

Several years ago, Gerhard started using the zebrafish, which can be easily bred and tends to exhibit diseases effects at an accelerated rate.

Yet the instruments needed to use these small and inexpensive fish for finding new drugs have not yet been brought to market.

The students have developed a working prototype screening plate that allows scientists to quickly expose zebrafish to ALS and mix c
'"/>

Contact: Justin Walden
jawalden@geisinger.edu
570-271-8083
Geisinger Health System
30-Jul-2007


Page: 1 2

Related biology news :

1. Johns Hopkins Bloomberg School of Public Health, Geisinger launch new environmental research group
2. Geisinger launches extensive study on obesity and related liver problem
3. New Geisinger Health System building green Center for Health Research
4. Doernbecher Childrens Hospital scientist earns coveted Javits award
5. UK scientists working to help cut ID theft
6. Smithsonian scientists show differing patterns of rainforest biodiversity
7. Weizmann Institute scientists discover a control mechanism for metastasis
8. Cornell scientists link E. coli bacteria to Crohns disease
9. UCLA scientists produce functioning neurons from human embryonic stem cells
10. ASBMB taps 8 scientists and 1 politician for top awards
11. UF, French scientists seek test to detect gene doping in athletes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: